Polar Asset Management Partners Inc. Sells 63,000 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Polar Asset Management Partners Inc. reduced its position in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 85.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,638 shares of the medical equipment provider's stock after selling 63,000 shares during the quarter. Polar Asset Management Partners Inc.'s holdings in BioLife Solutions were worth $266,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Mark Sheptoff Financial Planning LLC bought a new stake in BioLife Solutions in the third quarter worth approximately $28,000. Isthmus Partners LLC increased its stake in shares of BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 42,265 shares in the last quarter. 1620 Investment Advisors Inc. bought a new stake in shares of BioLife Solutions in the 2nd quarter valued at $35,000. Quest Partners LLC acquired a new position in shares of BioLife Solutions during the 3rd quarter valued at $57,000. Finally, GAMMA Investing LLC boosted its stake in BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider's stock worth $83,000 after acquiring an additional 748 shares in the last quarter. 93.24% of the stock is owned by institutional investors.

BioLife Solutions Trading Up 4.2 %

BLFS stock traded up $1.06 during mid-day trading on Friday, reaching $26.24. 217,345 shares of the company traded hands, compared to its average volume of 596,507. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The firm's 50 day moving average price is $24.42 and its 200 day moving average price is $23.38. BioLife Solutions, Inc. has a fifty-two week low of $12.45 and a fifty-two week high of $28.88.

Analyst Ratings Changes

BLFS has been the subject of several research analyst reports. TD Cowen lifted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. HC Wainwright decreased their target price on BioLife Solutions from $29.00 to $27.00 and set a "buy" rating for the company in a research report on Monday, November 18th. Northland Securities increased their price target on BioLife Solutions from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Friday, August 9th. Finally, Craig Hallum boosted their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, BioLife Solutions presently has an average rating of "Moderate Buy" and a consensus target price of $27.50.

Insider Activity

In other news, CRO Garrie Richardson sold 3,070 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the sale, the executive now owns 114,773 shares in the company, valued at $2,883,097.76. This represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Aby J. Mathew sold 25,000 shares of the business's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $21.17, for a total transaction of $529,250.00. Following the transaction, the executive vice president now owns 302,046 shares in the company, valued at approximately $6,394,313.82. This trade represents a 7.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,313 shares of company stock worth $1,572,899 over the last 90 days. 2.20% of the stock is currently owned by corporate insiders.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.